30: The Medicine Box: Kearney’s Saumya Krishna explains how ‘Make In India’ can fuel 4x growth in vaccines, biosimilars by 2026
Update: 2021-11-18
Description
The global vaccine industry has been stirred by the COVID-19 pandemic and Saumya Krishna of consulting firm Kearney estimates that the Indian vaccine industry can grow from $2 billion to $4-5 billion by 2025.
In this edition of The Medicine Box season 5, CNBC-TV18’s Ekta Batra discusses with Krishna a report by Kearney in collaboration with the Confederation of Indian Industry (CII). The report highlights how ‘Make In India’ can fuel 4x growth in biosimilars and vaccines by 2026.
Moreover, India is among the top 12 biotech destinations in the world with more than 2500 biotech companies. Indian firms have already launched over 98 biosimilar drugs in the market.
Krishna says the true opportunity for biologic drugs is in the global market and according to her billions worth of such drugs will go off patent in the next decade.
Tune in to the Medicine Podcast t find out more about vaccines, and ways to transform India’s biologics industry.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
